KR102435801B1 - Fc-함유 단백질의 정제 방법 - Google Patents

Fc-함유 단백질의 정제 방법 Download PDF

Info

Publication number
KR102435801B1
KR102435801B1 KR1020197003162A KR20197003162A KR102435801B1 KR 102435801 B1 KR102435801 B1 KR 102435801B1 KR 1020197003162 A KR1020197003162 A KR 1020197003162A KR 20197003162 A KR20197003162 A KR 20197003162A KR 102435801 B1 KR102435801 B1 KR 102435801B1
Authority
KR
South Korea
Prior art keywords
delete delete
protein
temperature
elution buffer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197003162A
Other languages
English (en)
Korean (ko)
Other versions
KR20190037247A (ko
Inventor
존 케이. 카우야
Original Assignee
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크 filed Critical 암젠 인크
Priority to KR1020227028721A priority Critical patent/KR102579850B1/ko
Publication of KR20190037247A publication Critical patent/KR20190037247A/ko
Application granted granted Critical
Publication of KR102435801B1 publication Critical patent/KR102435801B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Storage Device Security (AREA)
KR1020197003162A 2016-07-22 2017-07-21 Fc-함유 단백질의 정제 방법 Active KR102435801B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227028721A KR102579850B1 (ko) 2016-07-22 2017-07-21 Fc-함유 단백질의 정제 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365943P 2016-07-22 2016-07-22
US62/365,943 2016-07-22
PCT/US2017/043384 WO2018018011A2 (en) 2016-07-22 2017-07-21 Methods of purifying fc-containing proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227028721A Division KR102579850B1 (ko) 2016-07-22 2017-07-21 Fc-함유 단백질의 정제 방법

Publications (2)

Publication Number Publication Date
KR20190037247A KR20190037247A (ko) 2019-04-05
KR102435801B1 true KR102435801B1 (ko) 2022-08-25

Family

ID=59656168

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197003162A Active KR102435801B1 (ko) 2016-07-22 2017-07-21 Fc-함유 단백질의 정제 방법
KR1020227028721A Active KR102579850B1 (ko) 2016-07-22 2017-07-21 Fc-함유 단백질의 정제 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227028721A Active KR102579850B1 (ko) 2016-07-22 2017-07-21 Fc-함유 단백질의 정제 방법

Country Status (12)

Country Link
US (1) US11312745B2 (cg-RX-API-DMAC7.html)
EP (1) EP3487867A2 (cg-RX-API-DMAC7.html)
JP (2) JP7092744B2 (cg-RX-API-DMAC7.html)
KR (2) KR102435801B1 (cg-RX-API-DMAC7.html)
CN (2) CN109563125B (cg-RX-API-DMAC7.html)
AU (2) AU2017298984B2 (cg-RX-API-DMAC7.html)
CA (2) CA3031469C (cg-RX-API-DMAC7.html)
IL (2) IL285146B (cg-RX-API-DMAC7.html)
MA (1) MA45721A (cg-RX-API-DMAC7.html)
MX (2) MX2019000903A (cg-RX-API-DMAC7.html)
SG (1) SG11201900573UA (cg-RX-API-DMAC7.html)
WO (1) WO2018018011A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019343053A1 (en) * 2018-09-21 2021-04-15 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
WO2020077212A1 (en) * 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
CN113227785A (zh) * 2019-01-16 2021-08-06 瑞泽恩制药公司 识别和定量抗体片段化的方法和系统
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN112881675A (zh) * 2019-11-29 2021-06-01 广东菲鹏生物有限公司 IgM抗体检测稀释液
EP4132656A1 (en) 2020-04-09 2023-02-15 CytomX Therapeutics, Inc. Compositions containing activatable antibodies
EP4213958A1 (en) * 2020-09-16 2023-07-26 Waters Technologies Corporation Improved size exclusion chromatography utilizing low concentration amino acids in size exclusion chromatography mobile phase
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法
CN116165290B (zh) * 2021-12-17 2025-06-27 复旦大学 一种抗体药物研发流程中工程细胞株的筛选方法
CN116271982B (zh) * 2022-11-30 2024-01-09 杭州广科安德生物科技有限公司 一种血液高丰度蛋白免疫亲和柱的再生方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143199A1 (ja) * 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
JP2012531428A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
JP2013505238A (ja) * 2009-09-16 2013-02-14 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1999053059A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
SG156672A1 (en) * 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
US7834162B2 (en) * 2006-01-06 2010-11-16 Amgen Inc. Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US10982250B2 (en) * 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
MX2011001696A (es) * 2008-08-14 2011-03-25 Merck Sharp & Dohme Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a.
EP2445923B1 (en) * 2009-06-22 2018-09-05 Amgen, Inc Refolding proteins using a chemically controlled redox state
CN102382190B (zh) 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
EP2657254A4 (en) 2010-12-24 2014-01-08 Asahi Kasei Medical Co Ltd PROCESS FOR IMMOBILIZING THE TEMPERATURE-REACTIVE PROTEIN A
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
JP6420756B2 (ja) * 2012-03-28 2018-11-07 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
WO2014034644A1 (ja) 2012-08-27 2014-03-06 旭化成メディカル株式会社 温度応答性クロマトグラフィーによる抗体の精製方法
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP3176185A1 (en) * 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143199A1 (ja) * 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
JP2012531428A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
JP2013505238A (ja) * 2009-09-16 2013-02-14 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用

Also Published As

Publication number Publication date
AU2017298984A1 (en) 2019-02-07
CN115925780A (zh) 2023-04-07
SG11201900573UA (en) 2019-02-27
CN109563125B (zh) 2022-08-09
JP2022120138A (ja) 2022-08-17
EP3487867A2 (en) 2019-05-29
KR20220120716A (ko) 2022-08-30
AU2017298984B2 (en) 2023-08-31
WO2018018011A3 (en) 2018-03-01
CN109563125A (zh) 2019-04-02
IL285146B (en) 2022-09-01
IL264375B (en) 2021-09-30
WO2018018011A2 (en) 2018-01-25
JP7411020B2 (ja) 2024-01-10
KR102579850B1 (ko) 2023-09-18
IL264375A (en) 2019-02-28
CA3031469C (en) 2025-11-18
AU2023222915A1 (en) 2023-09-21
US11312745B2 (en) 2022-04-26
CN115925780B (zh) 2025-11-04
CA3031469A1 (en) 2018-01-25
MX2019000903A (es) 2019-05-15
MX2023006291A (es) 2023-06-13
JP7092744B2 (ja) 2022-06-28
MA45721A (fr) 2019-05-29
US20190127418A1 (en) 2019-05-02
KR20190037247A (ko) 2019-04-05
IL285146A (en) 2021-08-31
CA3218290A1 (en) 2018-01-25
JP2019528255A (ja) 2019-10-10

Similar Documents

Publication Publication Date Title
KR102435801B1 (ko) Fc-함유 단백질의 정제 방법
US9334319B2 (en) Low acidic species compositions
US20160115193A1 (en) Novel purification of antibodies using hydrophobic interaction chromatography
WO2012125735A1 (en) An integrated approach to the isolation and purification of antibodies
WO2013177115A2 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013158273A1 (en) Methods to modulate c-terminal lysine variant distribution
AU2018326458B2 (en) Method for purifying proteins
US11964998B2 (en) Method for purifying anti-IL-6 receptor antibodies
CN106414495A (zh) 抗体处理方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4